Pfizer has successfully completed its acquisition of Array BioPharma, welcoming their existing portfolio in melanoma and colorectal cancer, which when combined with Pfizer’s existing expertise in breast and prostate cancers could create an industry leading franchise.
‘We’re proud to bring Array’s broad pipeline and scientific talent into the Pfizer family,” said Mikeal Dolsten, Pfizer Chief scientific officer and president, worldwide research, development and medical. “By combining our leading research and development with Array, we can strengthen our potential to change patients’ lives through advanced science and technology break through.”
“Pfizer completes acquisition of Array BioPharma“
Pfizer plan to add Array’s colleagues to their books, and will maintain their operations in Cambridge, Massachusetts and Morrisville, and North Carolina. Facilities in Boulder, Colorado will become part of Pfizer’s Oncology Research & Development network.